GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Q-linea AB (OSTO:QLINEA) » Definitions » Institutional Ownership

Q-linea AB (OSTO:QLINEA) Institutional Ownership : 0.91% (As of May. 06, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Q-linea AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Q-linea AB's institutional ownership is 0.91%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Q-linea AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Q-linea AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Q-linea AB Institutional Ownership Historical Data

The historical data trend for Q-linea AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q-linea AB Institutional Ownership Chart

Q-linea AB Historical Data

The historical data trend for Q-linea AB can be seen below:

2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Institutional Ownership 2.53 0.36 0.36 0.36 0.36 0.21 0.17 1.06 0.90 0.90

Q-linea AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Q-linea AB Business Description

Traded in Other Exchanges
Address
Dag Hammarskjolds vag 52 A, Uppsala, SWE, SE-752 37
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.

Q-linea AB Headlines

No Headlines